ABCL - AbCellera Biologics GAAP EPS of -$0.51 misses by $0.04 revenue of $38M misses by $0.13M
2024-02-20 16:11:18 ET
More on AbCellera Biologics
- AbCellera Biologics: Continuing To Expand Partnerships
- AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024
- Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform
- Absci hits new 52-week high as race for AI drug discovery heats up
- KeyBanc sees opportunity in tech-enabled drug discovery stocks